Bionomics Inc.

Merck Sharp + Dohme Corp.

Merck Patent Gmbh

Ironwood Pharmaceuticals, Inc.

Cancer Therapeutics Crc Pty Limited

Andrew John Harvey

Dharam Paul

Bernard Luke Flynn

Ian M Bell

Brendan M Crowley

Rajinder Singh

Jorgen Alvar Mould

Jonathan Bayldon Baell

Justin Ripper

Belinda C Huff

Brian T Campbell

Kenneth J Leavitt

Nathan Wayne Kuchel

Thomas Avery

Thomas J Greshock

Bruno Giethlen

Jason Hugh Chaplin

Christophe Morice

Vanessa L Rada

Laurent Schaeffer

Julia Stephanie Crossman

Rachel Christine Cooke

Christophe Joseph

John M Sanders

Paul Anthony Stupple

Agnes Bombrun

Damian Wojciech Grobelny

Michelle Ang Camerino

William D Shipe

Joseph Leslie Duffy

Deodial Guy Guiadeen

Song Xue

Richard Charles Foitzik

Gurmit Singh Gill

Ahmad Hashash

Benjamin Joseph Morrow

Romina Lessene

Danny Ganame

Ian Peter Holmes

Gillian Elizabeth Lunniss

Jerome Molette

Catherine Fae Hemley

Cristina Donini

Isabelle Jeanclaude-Etter

Raymond E Forslund

Wilhelmus Johannes Antonius Kersten

Vasu Sethuraman

Rob Livingston

Patrick Bazzini

Linda M Suen

Veronique Colovray

Anthony J Roecker

Brad E Sleebs

Ian Phillip Street

Jean-Marie Contreras

Neil Choi

Fabrice Garrido

Sue O'Connor

Audrey Fluck

Joseph L Duffy

Aurelie Fromeyer

Julia Crossman

Aurelie Witzel

James Fells

Deodial G Guiadeen

Rachel Cooke

The present disclosure relates to compounds of formula I that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation

Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors

The present disclosure relates to compounds of formula I that are useful as modulators of &#x3b1;7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation

Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors

The present disclosure relates to compounds of formula (I) that are useful as modulators of &#x3b1;7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation. 

Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors

The present invention provides crystalline Forms FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and related methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using a crystalline Form FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and/or pharmaceutical compositions thereof. 

Salts, co-crystals, and polymorphs of an anxiolytic compound

Disclosed are compounds of Formula (IVA), or a salt thereof, and pharmaceutical formulations (pharmaceutical compositions) comprising those compounds, or a salt thereof: Formula (IVA), wherein 'R', 'R', &#x201c;R&#x201d;, &#x201c;R&#x201d;, &#x201c;R&#x201d;, are defined herein above, which compounds are believed suitable for use in positive modulation of the alpha 7 nicotinic acetylcholine receptor (&#x3b1;7 nAChR) receptors, for example, those found in the cerebral cortex and the hippocampus. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Alzheimer's disease (AD), schizophrenia, and Parkinson's disease (PD), or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease. 

Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof

The present disclosure relates to compounds of formula I that are useful as modulators of &#x3b1;7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation 

Allosteric modulators of nicotinic acetylcholine receptors

The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.

Amine derivatives as potassium channel blockers

The present invention relates to chemical compounds of formula (I), with the substituents as described in the specification, useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (&#x3b1;7 nAChR). The invention also relates to the use of these compounds in the treatment or prevention of a broad range of diseases in which the positive modulation of &#x3b1;7 nAChR is advantageous, including neurodegenerative and neuropsychiatric diseases and also neuropathic pain and inflammatory diseases. 

Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof-I

A crystalline Form B of compound 1 can be used in pharmaceutically compositions. The pharmaceutical compositions can be used in methods of treating a disease (e.g., a disease of the central nervous system). 

Crystalline form of an anxiolytic compound

The present invention provides amorphous arid crystalline forms of 1-ethyl-6-(indan-2-ylamino)-3-(morpholine-4-carbonyl)-1,8-naphthyridin-4-one (compound 1), and salts, co-crystals, and pharmaceutical compositions thereof. The invention also provides methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using the amorphous and crystalline forms, and salts, co-crystals, and pharmaceutical compositions thereof.

The present invention relates to chemical compounds useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (&#x3b1;7 nAChR).

&#x3b1;7 nicotinic acetylcholine receptor modulators and uses thereof-III

This invention relates to compounds of the formula (I): The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer, as well as the treatment of diseases ameliorated by the control and/or inhibition of lymphangiogenesis.

VEGFR3 inhibitors

Growing community of inventors

Goodwood, Australia

Andrew John Harvey